ERBB2 and breast cancer: HER2‐driven morphometric features were highly predominant in HER2 IHC 3+/ER‐negative BC cases compared to HER2 IHC 3+/ER‐positive and HER2 IHC 2+ with evidence of HER2 gene amplifications.